J Cancer 2022; 13(5):1388-1397. doi:10.7150/jca.69639 This issue Cite

Research Paper

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma

Yeong Hak Bang1*, Joon Ho Shim2,3*, Kyung Ju Ryu2*, Yeon Jeong Kim3, Myung Eun Choi2, Sang Eun Yoon4, Junhun Cho5, Bon Park2, Woong-Yang Park3, Won Seog Kim2,4, Seok Jin Kim2,4✉

1. Department of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
2. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
3. Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea.
4. Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
5. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea.
*These authors contributed equally as co-first authors.

Citation:
Bang YH, Shim JH, Ryu KJ, Kim YJ, Choi ME, Yoon SE, Cho J, Park B, Park WY, Kim WS, Kim SJ. Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. J Cancer 2022; 13(5):1388-1397. doi:10.7150/jca.69639. https://www.jcancer.org/v13p1388.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: The clinical utility of mRNA cargo in exosomes is unclear, although exosomes have potential as non-invasive biomarkers. This study aimed to investigate the feasibility of exosomal mRNA sequencing for monitoring disease status and predicting outcomes in non-Hodgkin lymphoma (NHL) patients.

Methods: Exosomes were isolated from archived serum samples of 33 patients with NHL who were registered into our prospective cohort: diffuse large B-cell lymphoma (DLBCL, n = 17), intravascular B-cell lymphoma (IVL, n = 1), primary mediastinal large B-cell lymphoma (PMBL, n = 4), follicular lymphoma (FL, n = 3), mantle cell lymphoma (MCL, n = 3), and extranodal NK/T-cell lymphoma (ENKTL, n = 5). Exosomal mRNA sequencing was performed, and its concordance with clinical course was analyzed and compared with those of circulating tumor DNA (ctDNA) mutations.

Results: Exosomal mRNA sequencing was performed successfully in 26 cases (79%, 26/33), whereas the remaining seven cases were not completed due to their small amount of RNA. The exosomal mRNA sequencing of DLBCL showed gene expression profiles consistent with activated B-cell-like and germinal center type. The longitudinal assessment of exosomal mRNA sequencing results in accordance with the clinical course showed that the post-treatment changes of exosomal mRNA expression were more consistent with treatment outcome than were those of ctDNA mutations. In particular, the exosomal mRNA expression of genes such as BCL2 and BCL6 was increased at the time of disease progression in DLBCL and FL patients.

Conclusions: This study demonstrated the feasibility of exosomal mRNA expression profiles as a biomarker for NHL patients. Our results might provide the rationale for studies to explore the potential of exosomal mRNA as a biomarker in NHL patients.

Keywords: Liquid biopsy, exosome, messenger RNA, non-Hodgkin lymphoma


Citation styles

APA
Bang, Y.H., Shim, J.H., Ryu, K.J., Kim, Y.J., Choi, M.E., Yoon, S.E., Cho, J., Park, B., Park, W.Y., Kim, W.S., Kim, S.J. (2022). Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. Journal of Cancer, 13(5), 1388-1397. https://doi.org/10.7150/jca.69639.

ACS
Bang, Y.H.; Shim, J.H.; Ryu, K.J.; Kim, Y.J.; Choi, M.E.; Yoon, S.E.; Cho, J.; Park, B.; Park, W.Y.; Kim, W.S.; Kim, S.J. Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. J. Cancer 2022, 13 (5), 1388-1397. DOI: 10.7150/jca.69639.

NLM
Bang YH, Shim JH, Ryu KJ, Kim YJ, Choi ME, Yoon SE, Cho J, Park B, Park WY, Kim WS, Kim SJ. Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. J Cancer 2022; 13(5):1388-1397. doi:10.7150/jca.69639. https://www.jcancer.org/v13p1388.htm

CSE
Bang YH, Shim JH, Ryu KJ, Kim YJ, Choi ME, Yoon SE, Cho J, Park B, Park WY, Kim WS, Kim SJ. 2022. Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. J Cancer. 13(5):1388-1397.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.